Plain-English translation of NCT06967610 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of three medications — , , and — can help people whose blood cancer (chronic lymphocytic leukemia or small lymphocytic lymphoma) has returned after earlier treatment. The three drugs work in different ways to attack cancer cells. The study is specifically designed to give this medication combination for a set amount of time rather than indefinitely.
Many people with this type of blood cancer eventually need new treatment after their initial therapy stops working. Researchers want to see if this three-drug combination can achieve deep remission (where cancer becomes undetectable) and whether giving it for a limited time is effective, which could reduce long-term side effects.
You likely qualify if…
You likely don't qualify if…
You would take three medications together by mouth on a regular schedule for about 25 weeks (approximately 6 months). During this time, you would have regular clinic visits for blood tests and check-ups to monitor how well the treatment is working and watch for any side effects. Doctors will check your bone marrow and blood samples at certain points to see if the cancer has become undetectable, and they will continue to track your health after treatment ends.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States